RU2018122830A - Ретинальные стволовые клетки - Google Patents
Ретинальные стволовые клетки Download PDFInfo
- Publication number
- RU2018122830A RU2018122830A RU2018122830A RU2018122830A RU2018122830A RU 2018122830 A RU2018122830 A RU 2018122830A RU 2018122830 A RU2018122830 A RU 2018122830A RU 2018122830 A RU2018122830 A RU 2018122830A RU 2018122830 A RU2018122830 A RU 2018122830A
- Authority
- RU
- Russia
- Prior art keywords
- isolated
- ora
- retinal stem
- stem cell
- region
- Prior art date
Links
- 230000002207 retinal effect Effects 0.000 title claims 12
- 210000000130 stem cell Anatomy 0.000 title claims 11
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000001575 pathological effect Effects 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 4
- 241000278713 Theora Species 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 210000001525 retina Anatomy 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000032578 Inherited retinal disease Diseases 0.000 claims 2
- 208000035719 Maculopathy Diseases 0.000 claims 2
- 208000032430 Retinal dystrophy Diseases 0.000 claims 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 2
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims 2
- 201000006321 fundus dystrophy Diseases 0.000 claims 2
- 201000001948 hypertensive retinopathy Diseases 0.000 claims 2
- 208000017532 inherited retinal dystrophy Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 108010003272 Hyaluronate lyase Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000011842 Serrate-Jagged Proteins Human genes 0.000 claims 1
- 108010036039 Serrate-Jagged Proteins Proteins 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
- 210000004127 vitreous body Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Developmental Biology & Embryology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Acoustics & Sound (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Claims (16)
1. Выделенная ретинальная стволовая клетка для лечения офтальмологического патологического состояния или заболевания, которая выделена из области ora terminalis и/или из области ora serrata сетчатки млекопитающего в постнатальном периоде.
2. Выделенная ретинальная стволовая клетка по п. 1, выделенная из области сетчатки, которая включает указанную область ora terminalis и/или ora serrata; образованная предпочтительно указанной областью ora terminalis и/или ora serrata; более предпочтительно образованная по существу указанной областью ora terminalis и/или ora serrate; с максимальным предпочтением образованная исключительно указанной областью ora terminalis и/или ora serrata, и не выделенная из других областей сетчатки.
3. Выделенная ретинальная стволовая клетка по п. 1 или 2, которая является недифференцированной и мультипотентной; предпочтительно, она является мультипотентной и способна дифференцироваться во все разные типы нервной ретинальной клетки.
4. Способ выделения ретинальной стволовой клетки из млекопитающего в постнатальном периоде, включающий следующие стадии:
(a) отделение всей или части ora terminalis и/или ora serrata от глаза субъекта,
(b) культивирование указанных отделенных ora terminalis и/или ora serrata в среде, что приводит к образованию сфер и/или небольших групп (кластеров) клеток, которые содержат ретинальные стволовые клетки,
(c) размещение полученных в результате сфер и/или кластеров клеток в среде, которая содержит ферменты трипсин и гиалуронидазу,
(d) блокирование ферментов одним или более ингибитором, и
(e) выделение полученных ретинальных стволовых клеток из полученных сфер и/или кластеров клеток.
5. Выделенная ретинальная стволовая клетка для лечения офтальмологического патологического состояния или заболевания, полученная способом, как определено в п. 4.
6. Выделенная ретинальная стволовая клетка по любому из пп. 1-3 или 5, где офтальмологическое патологическое состояние или заболевание, подлежащее лечению, включает одно или более из: пигментного ретинита, макулопатии, диабетической ретинопатии, гипертонической ретинопатии и дистрофии сетчатки.
7. Фармацевтическая композиция для лечения офтальмологического патологического состояния или заболевания, содержащая
выделенную ретинальную стволовую клетку, по любому из пп 1-3 или 5, и/или ее потомство, и
по меньшей мере один фармацевтически приемлемый носитель и/или эксципиент.
8. Фармацевтическая композиция по п. 7 для инъекции в стекловидное тело.
9. Способ лечения офтальмологического патологического состояния или заболевания у субъекта, включающий стадию введения указанному субъекту, нуждающемся в таком лечении эффективного количества выделенных ретинальных стволовых клеток по п. 1 и/или их потомство, где офтальмологическое патологическое состояние или заболевание, подлежащее лечению включает, не ограничиваясь ими, одно или более из: пигментного ретинита, макулопатии, диабетической ретинопатии, гипертонической ретинопатии и дистрофии сетчатки.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH01907/15 | 2015-12-23 | ||
| CH01907/15A CH711966A2 (it) | 2015-12-23 | 2015-12-23 | Cellule staminali retinali. |
| PCT/IB2016/057830 WO2017109699A1 (en) | 2015-12-23 | 2016-12-20 | Retinal stem cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018122830A true RU2018122830A (ru) | 2020-01-23 |
Family
ID=57963379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018122830A RU2018122830A (ru) | 2015-12-23 | 2016-12-20 | Ретинальные стволовые клетки |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190010453A1 (ru) |
| EP (1) | EP3394249A1 (ru) |
| JP (1) | JP2019505199A (ru) |
| KR (1) | KR20180096767A (ru) |
| CN (1) | CN108699527A (ru) |
| AU (1) | AU2016379194A1 (ru) |
| CA (1) | CA3009595A1 (ru) |
| CH (1) | CH711966A2 (ru) |
| RU (1) | RU2018122830A (ru) |
| WO (1) | WO2017109699A1 (ru) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2216439A1 (en) * | 1996-09-25 | 1998-03-25 | Derek Van Der Kooy | Pharmaceuticals containing retinal stem cells |
| AU2001234998B2 (en) * | 2000-02-11 | 2006-06-08 | Childrens Hospital Of Orange County A California Corporation | Isolation and transplantation of retinal stem cells |
| US20080124276A1 (en) * | 2006-07-24 | 2008-05-29 | Lifeline Cell Technology | Synthetic cornea from retinal stem cells |
| EP2554661B2 (en) * | 2007-04-18 | 2018-02-21 | Hadasit Medical Research Services & Development Limited | Stem cell-derived retinal pigment epithelial cells |
| EP2251028A1 (en) * | 2009-05-12 | 2010-11-17 | Biocompatibles Uk Ltd. | Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor |
| US8563304B2 (en) * | 2011-06-14 | 2013-10-22 | The Schepens Eye Research Institute | Low oxygen culture conditions for maintaining retinal progenitor cell multipotency |
| CN102618490B (zh) * | 2012-03-20 | 2013-12-25 | 中国人民解放军第三军医大学第一附属医院 | 一种诱导视网膜干细胞分化为感光细胞的方法 |
| CN103409363B (zh) * | 2013-08-06 | 2015-01-21 | 中国人民解放军总医院 | 感光前体细胞与视网膜组织体外共培养方法 |
-
2015
- 2015-12-23 CH CH01907/15A patent/CH711966A2/it not_active Application Discontinuation
-
2016
- 2016-12-20 EP EP16834114.7A patent/EP3394249A1/en not_active Withdrawn
- 2016-12-20 JP JP2018533799A patent/JP2019505199A/ja active Pending
- 2016-12-20 CN CN201680080990.1A patent/CN108699527A/zh active Pending
- 2016-12-20 CA CA3009595A patent/CA3009595A1/en not_active Abandoned
- 2016-12-20 US US16/065,795 patent/US20190010453A1/en not_active Abandoned
- 2016-12-20 WO PCT/IB2016/057830 patent/WO2017109699A1/en not_active Ceased
- 2016-12-20 RU RU2018122830A patent/RU2018122830A/ru not_active Application Discontinuation
- 2016-12-20 AU AU2016379194A patent/AU2016379194A1/en not_active Abandoned
- 2016-12-20 KR KR1020187021149A patent/KR20180096767A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA3009595A1 (en) | 2017-06-29 |
| JP2019505199A (ja) | 2019-02-28 |
| KR20180096767A (ko) | 2018-08-29 |
| US20190010453A1 (en) | 2019-01-10 |
| CH711966A2 (it) | 2017-06-30 |
| AU2016379194A1 (en) | 2018-07-12 |
| EP3394249A1 (en) | 2018-10-31 |
| WO2017109699A1 (en) | 2017-06-29 |
| CN108699527A (zh) | 2018-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vargas et al. | Soluble tumor necrosis factor alpha promotes retinal ganglion cell death in glaucoma via calcium-permeable AMPA receptor activation | |
| Gesteira et al. | Hyaluronan rich microenvironment in the limbal stem cell niche regulates limbal stem cell differentiation | |
| Tezel | Immune regulation toward immunomodulation for neuroprotection in glaucoma | |
| Lu et al. | Human adult bone marrow-derived somatic cells rescue vision in a rodent model of retinal degeneration | |
| Tzameret et al. | Epiretinal transplantation of human bone marrow mesenchymal stem cells rescues retinal and vision function in a rat model of retinal degeneration | |
| Rehni et al. | Amniotic fluid derived stem cells ameliorate focal cerebral ischaemia-reperfusion injury induced behavioural deficits in mice | |
| Voisin et al. | Stem cell therapy in retinal diseases | |
| PH12021550621A1 (en) | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness | |
| WO2016201450A3 (en) | Cancer treatment and diagnosis | |
| MX2018010508A (es) | Preparaciones mejoradas de celulas progenitoras hepaticas adultas. | |
| HK1250940A1 (zh) | 用於预防上皮细胞的增殖和上皮-间充质转换的组合物和方法 | |
| KR20140040696A (ko) | 간엽줄기세포 및 면역조절 t 세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 | |
| MX2021007709A (es) | Composiciones farmacéuticas oftálmicas y procedimientos para el tratamiento de las enfermedades de la superficie ocular. | |
| NZ785158A (en) | Topical cyclosporine-containing formulations and uses thereof | |
| US20240060048A1 (en) | Method for promoting and improving properties of adipose tissue, tissue and cells obtained by said method | |
| EA201790563A1 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| Rahimian et al. | Advances in exosome-based therapies for the repair of peripheral nerve injuries | |
| RU2021135194A (ru) | Способы и аппараты для подготовки клеточных популяций для клеточной терапии | |
| Crnej et al. | Corneal inflammation after miniature keratoprosthesis implantation | |
| Zhao et al. | The effects of sonic hedgehog on retinal Müller cells under high-glucose stress | |
| RU2018122830A (ru) | Ретинальные стволовые клетки | |
| JP2016522830A5 (ru) | ||
| Huang et al. | Extracellular signal-regulated kinase 1/2 pathway is insufficiently involved in the neuroprotective effect by hydrogen sulfide supplement in experimental glaucoma | |
| Liu et al. | Electroacupuncture improves retinal function in myopia Guinea pigs probably via inhibition of the RhoA/ROCK2 signaling pathway | |
| Chudickova et al. | Targeted neural differentiation of murine mesenchymal stem cells by a protocol simulating the inflammatory site of neural injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20191223 |